Considering the genetic heterogeneity of KRAS-mutant lung cancers, and the multitude of drug combinations entering clinical testing, it is crucial to identify vulnerabilities conferred by specific genomic alterations and develop biomarkers that can predict response to KRASG12C inhibitor combinations that may help guide patient selection. The gene discussed is KRAS; the disease is lung carcinoma.